Navigation Links
Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121
Date:11/20/2012

PARAMUS, N.J., Nov. 20, 2012 /PRNewswire/ -- PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced the screening of patients with End Stage Liver Disease (ESLD) for use in its clinical trial of UMK-121.

Michael Cohen, the Chief Executive Officer of the Company stated: "At least thirty (30) patients have been screened so far pursuant to inclusion and exclusion criteria approved by the Institutional Review Board as part of the protocol.  The initiation of screening is the first step towards commencement of the clinical trial of UMK-121."

About Proteonomix, Inc.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at www.proteonomix.com and www.proteoderm.com.

Forward-looking statements:

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.


'/>"/>
SOURCE Proteonomix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Proteonomix, Inc. Announces Finalizing ECRF for Its Clinical Trial of UMK 121 in Patients with End Stage Liver Disease
2. Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
3. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
4. ShangPharma Announces Third Quarter 2012 Results
5. Dr. TATTOFF Announces Use of Astanza Laser Tattoo Removal Systems for New Phoenix Location
6. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
7. Sensus Healthcare Announces Health Canada Approval
8. Neusoft Medical Systems, USA Announces Alignment with Landauer Medical Physics
9. Grupo Casa Saba Reports - Grupo Casa Saba Announces its Intention to Delist From the New York Stock Exchange
10. Landauer Medical Physics Announces Alignment With Neusoft Medical Systems, USA
11. The Michael J. Fox Foundation Announces Fourth Quarter Participants in Partnering Program Between Awardees and Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
Breaking Medicine Technology:
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):